Pharmasset Inc Headquarters
The links below provide all the necessary information about Pharmasset Inc Headquarters. Also there you will find information about the address, phone numbers, emails and much more.
Pharmasset - Crunchbase Company Profile & Funding
- https://www.crunchbase.com/organization/pharmasset
- Contact Email [email protected]. Phone Number +1 650-574-3000. Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis ...
Pharmasset Company Profile: Acquisition & Investors
- https://pitchbook.com/profiles/company/41584-06
- Information on acquisition, funding, cap tables, investors, and executives for Pharmasset. Use the PitchBook Platform to explore the full profile. Log in Request a free trial. Request a free trial Log in. Products; Solutions; ... EUROPEAN Headquarters +44 (0) 20 8037.2308; 1st Floor Saffron House; 6-10 Kirby Street; London EC1N 8TS; United ...
Pharmasset, Inc. | LinkedIn
- https://www.linkedin.com/company/pharmasset-inc-
- Pharmasset's primary focus is on the development of oral therapeutics for the treatment of Hepatitis C. Pharmasset, Inc. was founded in 1998 and is …
Jobs with Pharmasset, Inc. - BioSpace
- https://www.biospace.com/employer/517367/pharmasset-inc-/
- Pharmasset, Inc. to Change Design of Hepatitis C Treatment Study, Says Trial Change Won't Affect Gilead Sciences, Inc. Takeover. 12/19/2011. Gilead Sciences, Inc. to Acquire Pharmasset, Inc. for $11 Billion. 11/22/2011. Pharmasset, Inc. Reports Fiscal Year End 2011 Financial Results. 11/15/2011. Pharmasset, Inc. to Present at the Lazard Capital ...
Pharmasset, Inc. (NASDAQ:VRUS) : Articles :: Law360
- https://www.law360.com/companies/pharmasset-inc
- The latest litigation news involving the company Pharmasset, Inc. (NASDAQ:VRUS)
PHARMASSET INC - Securities Registration Statement (S-1) …
- https://sec.edgar-online.com/pharmasset-inc/s-1-securities-registration-statement/2006/05/08/section81.aspx
- THIS LICENSE AGREEMENT is made and entered into as of this 8th day of December, 1998, by and between EMORY UNIVERSITY, a Georgia non-profit corporation with principal offices located at 1380 South Oxford Road, Atlanta, Georgia 30322 (hereinafter “EMORY”), and PHARMASSET, LTD., a Barbados corporation with corporate headquarters …
20 Biggest Companies In Princeton, NJ - Zippia
- https://www.zippia.com/company/best-biggest-companies-in-princeton-nj/
- Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. ... Deloitte's U.S. headquarters at 30 Rockefeller Plaza in Manhattan was awarded the U.S. Green Building Council's Leadership in Energy and Environmental Design (LEED) Certification at the ...
Pharmasset, Inc.
- https://investors.gilead.com/static-files/8195aaf5-8d6d-4b44-a807-c8f127894b0e
- common stock, par value $0.001 (“Shares”), of Pharmasset, Inc., a Delaware corporation (“Pharmasset”), at a price of $137 per Share, net to the seller in cash (less any required withholding taxes and without interest) (the “Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase dated
Gilead Sciences - Wikipedia
- https://en.wikipedia.org/wiki/Gilead_Sciences
- Gilead Sciences, Inc. / ˈ ɡ ɪ l i ə d /, is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and influenza, including ledipasvir/sofosbuvir and sofosbuvir.Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
Pharmasset Inc 10-Q - RealDealDocs
- https://www.realdealdocs.com/viewdocument.aspx?DocumentID=2939717
- Item 1. Item 1A. Item 6. The “Company,” “Pharmasset,” “we,” and “us” as used in this Form 10-Q refer to Pharmasset, Inc., a Delaware corporation. Pharmasset, our logo and Racivir are our trademarks. Other trademarks mentioned in this Form 10 …
Gilead Sciences, Inc.
- https://www.gilead.com/
- May 02, 2022. Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation. April 28, 2022. Gilead Sciences Announces First Quarter 2022 Financial Results.
Did you find out everything you wanted about Pharmasset Inc Headquarters?
We are sure that the information collected for you about Pharmasset Inc Headquarters turned out to be more than enough.
